Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 221,894,038 papers from all fields of science
Search
Sign In
Create Free Account
Anti-FGFR2 Monoclonal Antibody FPA144
Known as:
FPA144
A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth factor receptor type 2b (FGFR2b), with potential…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).
M. Tejani
,
E. Cheung
,
+9 authors
D. Catenacci
Journal of Clinical Oncology
2019
Corpus ID: 86741388
91 Background: GC with FGFR2b overexpression or FGFR2 amplification is associated with a poor prognosis. Bemarituzumab (bema…
Expand
2018
2018
FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and…
D. Catenacci
,
P. Enzinger
,
+8 authors
P. Eisenberg
2018
Corpus ID: 81618305
TPS4135Background: FGFR2b overexpression and FGFR2 gene amplification occurs in approximately 10% of patients with gastric cancer…
Expand
2017
2017
Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.
D. Catenacci
,
S. Rha
,
+16 authors
Jeeyun Lee
2017
Corpus ID: 79771287
4067Background: FGFR2b-overexpressing gastric cancer is characterized by poor prognosis. FPA144, a humanized monoclonal IgG1…
Expand
2016
2016
FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors.
J. Bendell
,
S. Rogers
,
+5 authors
D. Rasco
2016
Corpus ID: 78353422
140 Background: FPA144 is a humanized monoclonal IgG1 antibody directed against the 2b Isoform of thefibroblast growth factor…
Expand
2016
2016
Abstract 1407: FPA144, a therapeutic monoclonal antibody targeting the FGFR2b receptor, promotes antibody dependent cell-mediated cytotoxicity and stimulates sensitivity to PD-1 in the 4T1 syngeneic…
Janine Powers
,
Servando Palencia
,
+5 authors
K. Pierce
2016
Corpus ID: 79435466
2016
2016
Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+ gastric cancer and advanced solid tumors.
Jeeyun Lee
,
J. Bendell
,
+7 authors
D. Rasco
2016
Corpus ID: 80324880
2502Background: FGFR2b-overexpressing gastric cancer is a distinct setting with poor prognosis. FPA144, a humanized monoclonal…
Expand
2016
2016
Engineering of FPA144 for ADCC Drives Innate and Adaptive Responses
Janine Powers
,
Servando Palencia
,
+5 authors
K. L. Pierce
2016
Corpus ID: 88845757
2014
2014
Abstract 5446: FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification
A. T. Gemo
,
Amit M. Deshpande
,
+6 authors
K. L. Pierce
2014
Corpus ID: 72524137
A subset of patients with gastric cancer have an amplification of the receptor tyrosine kinase fibroblast growth factor receptor…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE